Cost of Revenue Comparison: Alkermes plc vs Amneal Pharmaceuticals, Inc.

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. Alkermes plc and Amneal Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Alkermes plc started with a cost of revenue of approximately $448 million in 2014, peaking at around $693 million in 2019, before dropping significantly to $218 million in 2022. This represents a 68% decrease from its peak. In contrast, Amneal Pharmaceuticals, Inc. has seen a steady increase, starting at $336 million in 2014 and reaching $1.57 billion by 2023, marking a 367% rise. This divergence highlights the strategic differences in managing production costs and scaling operations. As the pharmaceutical industry evolves, these insights provide a window into how companies adapt to market demands and operational challenges.